Valeant to Participate at the Deutsche Bank 25th Annual Leveraged Finance Conference

LAVAL, Quebec, Sept. 27, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer; Linda LaGorga, senior vice president, Finance, and treasurer; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications; are scheduled to participate at the Deutsche Bank 25(th) Annual Leveraged Finance Conference in Scottsdale, Ariz. on Oct. 4, 2017 at 8:00 a.m. MST (11:00 a.m. EDT).

A live webcast and audio archive of the event will be available on the Investor Relations page of the Valeant web site at:

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at

    Investor Contact:          Media Contact:

    Arthur Shannon             Lainie Keller

    (514) 856-3855             (908) 927-0617

    (877) 281-6642 (toll free)

View original content:

SOURCE Valeant Pharmaceuticals International, Inc.